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Background: The sore throat pain model has been conducted by different clinical investigators to demonstrate the
efficacy of acute analgesic drugs in single-dose randomized clinical trials. The model used here was designed to
study the multiple-dose safety and efficacy of lozenges containing flurbiprofen at 8.75 mg.
Methods: Adults (n = 198) with moderate or severe acute sore throat and findings of pharyngitis on a Tonsillo-
Pharyngitis Assessment (TPA) were randomly assigned to use either flurbiprofen 8.75 mg lozenges (n = 101) or
matching placebo lozenges (n = 97) under double-blind conditions. Patients sucked one lozenge every three to six
hours as needed, up to five lozenges per day, and rated symptoms on 100-mm scales: the Sore Throat Pain Intensity
Scale (STPIS), the Difficulty Swallowing Scale (DSS), and the Swollen Throat Scale (SwoTS).
Results: Reductions in pain (lasting for three hours) and in difficulty swallowing and throat swelling (for four hours)
were observed after a single dose of the flurbiprofen 8.75 mg lozenge (P <0.05 compared with placebo). After
using multiple doses over 24 hours, flurbiprofen-treated patients experienced a 59% greater reduction in throat
pain, 45% less difficulty swallowing, and 44% less throat swelling than placebo-treated patients (all P <0.01). There
were no serious adverse events.
Conclusions: Utilizing the sore throat pain model with multiple doses over 24 hours, flurbiprofen 8.75 mg lozenges
were shown to be an effective, well-tolerated treatment for sore throat pain. Other pharmacologic actions (reduced
difficulty swallowing and reduced throat swelling) and overall patient satisfaction from the flurbiprofen lozenges
were also demonstrated in this multiple-dose implementation of the sore throat pain model.
Trial registration: This trial was registered with ClinicalTrials.gov, registration number: NCT01048866, registration
date: January 13, 2010.
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The sore throat pain model has been used to demonstrate
the efficacy of acute analgesic drugs and dosages of these
drugs in single-dose randomized placebo-controlled stud-
ies [1-4]. As for most acute pain conditions, patients with
painful pharyngitis due to upper respiratory tract infection
(URTI) often require repeated treatment beyond one or
two doses, especially on the first day of treatment, until* Correspondence: bschachtel@srcresearch.net
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unless otherwise stated.the URTI resolves [5,6]. However, the vis medicatrix nat-
urae of sore throat [7-9], earache [10], and other types of
acute pain [11,12] makes it difficult to distinguish an ac-
tive analgesic from placebo when treatments are re-tested
over time, even over 24 hours.
Recognizing this investigational challenge in examining
multiple-dose efficacy in patients with an acute, self-
limited infectious disease, we employed four specific prin-
ciples of research architecture in order to tighten the
design of this multiple-dose trial. First, to avoid confusion
with other expressions of URTI that can also cause a sore
throat (such as laryngitis) and might respond differently to
treatment, we enrolled only patients with sore throat dueral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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on the Tonsillo-Pharyngitis Assessment (TPA), an index
of distinct clinical features of pharyngitis [1,13,14]. Mea-
surements on the TPA also helped confirm that patients
in the treatment groups had the same severity of the phys-
ical condition causing sore throat.
Second, to fully characterize the many expressions of
throat dis-ease which the patients described, we sought
to evaluate other dimensions of throat pain in addition
to the evaluative quality of ‘sore’ throat (pain intensity).
We asked the patients to evaluate two other prominent
throat-related symptoms which they also complained of,
the sensation of a ‘swollen throat’, a sensory quality com-
monly reported by patients with sore throat, as well as
‘difficulty swallowing’, a throat function (dysphagia, dis-
tinctly different from odynophagia) [4,5,15-18].
Third, because patients with acute sore throat require
treatment mostly during the early course of disease, we
sought to enroll patients within three days of their first
throat symptom (even a mild sore throat, such as a ‘throat
tickle’). Thus, we would be more likely to observe patients
who provided assessments of sore throat throughout the
first 24 hours of the clinical trial. Also, to help assure that
symptom severity would be more likely to persist for at
least 24 hours and efficacy could be assessed over this
treatment period, patients were eligible only if they re-
ported at least a moderate severity of sore throat pain,
swollen throat, and difficulty swallowing at baseline.
Previous studies have demonstrated the efficacy and
safety of a single dose of a lozenge containing the nonste-
roidal anti-inflammatory drug flurbiprofen in patients
with sore throat [7-9,19,20], including a single-dose study
on different dosages of flurbiprofen lozenge [21]. Here we
present the results of a clinical trial utilizing the sore
throat pain model to examine the efficacy and safety of
multiple doses of a lozenge containing flurbiprofen
8.75 mg, with a focus on the initial 24 hours of treatment.
Methods
Study design
This was a randomized (ratio 1:1), double-blind, placebo-




Size of tonsils Nor
Number of oropharyngeal enanthems (vesicles, petechiae, or exudates)
Largest size of anterior cervical lymph nodes
Number of anterior cervical lymph nodes
Maximum tenderness of some anterior cervical lymph nodes Nsubject was enrolled in November 2009 and the last sub-
ject completed in March 2011. The study was conducted
in accordance with the International Conference on
Harmonization Good Clinical Practice and the ethical
principles contained within the Declaration of Helsinki
(South Africa, 1996). The study also complied with the
Code of Federal Regulations (CFR) of the United States
Food and Drug Administration (FDA) and the United
States Good Clinical Practice Regulations. The study
protocol was reviewed and approved by The New York
University School of Medicine’s Institutional Review Board,
Compass Institutional Review Board and IntegReview Eth-
ical Review Board. The study was registered with the Clini-
calTrials.gov registry, registration number: NCT01048866.
Patient selection
Patients were screened by the study investigators at re-
search sites in the United States after seeking medical
care for sore throat, being referred to the trial site, or
responding to advertisements about this study. All par-
ticipants provided written informed consent prior to
participation in the study. Adults (≥18 years) were in-
cluded if they had a sore throat of recent onset (≤3 days),
moderate or severe pain on the Throat Pain Scale (a
four-category pain intensity scale), at least one symptom
of URTI on the URTI Questionnaire [2,14], objective
findings of pharyngeal inflammation (≥5 on the TPA;
Table 1) [1,13,14], and throat symptoms on three patient-
reported outcome measures: sore throat pain rated more
than or equal to 66 mm on the Sore Throat Pain Intensity
Scale (STPIS); difficulty swallowing rated more than or
equal to 50 mm on the Difficulty Swallowing Scale (DSS);
and the sensation of a swollen throat rated more than or
equal to 33 mm on the Swollen Throat Scale (SwoTS).
See Figure 1 for descriptions of the three symptom rating
scales.
Patients were ineligible if they displayed confounding
features of URTI: mouth breathing which causes throat
drying, coughing which causes throat discomfort, or any
disease that could compromise respiratory function. Pa-
tients were also ineligible if they had a history of allergic
reaction or hypersensitivity to aspirin or other nonsteroidalPoints 1 Point 2 Points 3 Points
≤ 98.6°F 98.7 – 98.9°F 99.0 – 99.9°F ≥ 100.0°F
rmal/pink Slightly red Red Beefy red
mal/absent Slightly enlarged Moderately enlarged Much enlarged
None Few Several Many
Normal Slightly enlarged Moderately enlarged Much enlarged
Normal Slightly increased Moderately increased Greatly increased
ot tender Slightly tender Moderately tender Very tender
A) The patient was instructed to swallow and:
“Place a line on the ‘Sore Throat Scale’ that best characterizes the 
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Figure 1 Visual analog scales to assess patient-reported outcomes.
The 100-mm visual analog scales used were A) the Sore Throat Pain
Intensity Scale (STPIS) to assess sore throat pain, B) the Difficulty
Swallowing Scale (DSS) to assess difficulty swallowing, and C) the
Swollen Throat Scale (SwoTS) to assess the sensation of a swollen throat.
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or renal dysfunction. Patients were excluded if they had
used any throat lozenge, throat spray, cough drop, or
menthol-containing product within one hour prior to
study screening, used any ‘cold medication’ or immediate-
release analgesic within the previous four hours, used any
sustained-release analgesic within the previous 12 hours,
taken an antibiotic for an acute disease within 24 hours,
or any quinolone antibiotic or inhaled therapy in the pre-
vious week.
Study medications
Under double-blind conditions, patients were randomly
allocated to receive sugar-based, flavored flurbiprofen
8.75 mg lozenges or sugar-based, identically flavored pla-
cebo lozenges (containing the same vehicle ingredients as
the flurbiprofen lozenge). Randomization was achieved
using a computer-generated randomization schedule pro-
vided by a statistician who was not involved in the analysis
of the study. The patients, study investigators, and all
other study personnel remained blinded to the treatment
allocation after randomization.
Patients were instructed to suck one lozenge (flurbi-
profen 8.75 mg or placebo) and were then not permitted
to have anything by mouth for the next two hours. Pa-
tients were assessed onsite for the first two hours, then
discharged with a supply of the same trial lozenges (one
lozenge to be used as needed every three to six hours, up
to five lozenges in a 24-hour period) and acetaminophen650 mg tablets (to be taken as needed every four to six
hours if there was inadequate relief from the trial lozenge).
No other medications were permitted during this 24-hour
period. Over 24 hours (while awake), patients used a diary
to record hourly assessments of sore throat pain, swollen
throat, and difficulty swallowing, their medication con-
sumption, and any adverse events (AEs). A follow-up visit
was conducted for the 24-hour assessments. Over the fol-
lowing six days patients assessed secondary outcomes
before and after each self-dosing. At the end of the seven-
day observation period patients returned to the site for
final assessments and review of AEs and were discharged
from the study.
Assessments
At baseline, all patients were examined for physical find-
ings of tonsillo-pharyngitis, as measured on the TPA
(Table 1), and for a global assessment of the severity of
pharyngeal inflammation, on the categorical Practi-
tioner’s Assessment of Inflammation, or PrAoI (none,
mild, moderate, severe). All patients had a throat culture
performed to determine the presence of group A beta-
hemolytic streptococcus in the oropharynx. Upon re-
ceipt of culture results at 24 to 48 hours, all patients
with group A infection received antibiotics and symp-
tomatic patients with group C streptococcus infection
also received antibiotics. All patients continued in the
study after the initial 24 hours and were included in the
efficacy analyses regardless of their streptococcus infec-
tion or antibiotic treatment status.
Previously validated 100-mm visual analog scales
(Figure 1) were used to record the symptoms of sore
throat pain intensity, difficulty swallowing, and the sensa-
tion of a swollen throat [1,4,18,22,23]. Patients assessed
throat symptoms on the STPIS, DSS, and SwoTS at base-
line, one hour, and two hours after the first dose, then
every hour for the remainder of the first 24-hour study
period (when awake), and again at pretreatment, and one
and two hours after each dose taken over days two to
seven.
Sore throat relief was also measured at one hour and
two hours after the first dose on a validated scale, the
Sore Throat Relief Rating Scale (STRRS), a six-category
scale ranging from ‘no relief ’ to ‘complete relief ’ [15,23].
At the 24-hour visit patients were asked to rate their
satisfaction or dissatisfaction with the study medication
by completing the Patient Satisfaction Scale, a seven-
category scale ranging from ‘extremely dissatisfied’ to
‘extremely satisfied’ [24].
Statistical analyses
The primary endpoint of this study was the time-weighted
summed difference in pain intensity on the STPIS over
24 hours after the first dose of study medication (SPID24).
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assuming a 20% effect size [7-9] with 80% power, 200 pa-
tients were needed for this study (100 patients on each
treatment).
Efficacy was calculated using least square (LS) means,
and analysis of variance (ANOVA) was used to compare
flurbiprofen 8.75 mg and placebo groups, with treatment
and site included as a fixed effect and the relevant base-
line (baseline STPIS, DSS, or SwoTS score) included as
a covariate. The time-weighted summed differences in
DSS and SwoTS over 24 hours were similarly evaluated.
The time-weighted summed differences for all three out-
comes were assessed over two hours after each dosing
over days two to seven. If a patient used rescue medica-
tion for pain, all subsequent STPIS, DSS, and SwoTS
scores in the 24-hour interval were assigned the baseline
value (baseline observation carried forward, BOCF).
Missing scores for time-weighted summed differences
from baseline were imputed using linear interpolation,
assuming the time of the missing assessment to be the
nominal time since the first dose, in order to give a more
reliable approximation of the AUC from the non-
missing data. Two-sided statistical tests were performed
with significance determined by reference to the 5% sig-
nificance level.
Wilcoxon rank sum tests were performed to analyze the
data obtained for the pharyngeal inflammation category
(on the PrAoI), duration of sore throat, size of tonsils (on
the TPA), sore throat relief, and patient satisfaction. The
chi-square test was performed to analyze the sex and AE
data, and two-sided statistical t-tests were used to analyze














Figure 2 Patient disposition. *Discontinuation was due to headache.To determine the efficacy of a single dose of study
medication as measured on the STPIS, DSS, and SwoTS
[1,4,5,22,23], the absolute change from baseline was cal-
culated over the six hours after the initial single dose of
study medication. The odds of achieving at least a 20%
reduction in symptom severity (on the STPIS, DSS, or
SwoTS) with flurbiprofen 8.75 mg compared with pla-
cebo was assessed using logistic regression, after adjust-
ing for site effects. Treatment effect was also analyzed
by determining the cumulative percentage of responders
(patients who reported at least a 20% reduction from
baseline in STPIS score) over the initial six hours. These
data were used to calculate the absolute risk difference
(ARD) between the proportion of responders for the two
treatment groups and to calculate the number needed to
treat (NNT; 1/ARD). For patients who used additional
study or rescue medication in the initial six-hour treat-
ment period, all subsequent changes in STPIS, DSS, and
SwoTS scores over six hours were set to zero according
to the BOCF convention. All statistical analyses were
performed using SAS version 9.2, SAS Institute Inc.,
Cary, NC, USA.
Results
Patient enrollment, disposition, and demographics
Of the 336 patients screened, 198 patients were random-
ized to receive either flurbiprofen 8.75 mg (n = 101) or
placebo (n = 97) lozenges (Figure 2). One patient (in the
placebo treatment group) withdrew consent and did not
record any information between 2 and 24 hours post ini-
tial dose, eight patients (four in each treatment group)












Did not meet inclusion criteria=127
Did meet exclusion criteria=11
ed
Table 2 Patient demographics and baseline characteristics
Characteristic Flurbiprofen





Sex, male, n (%) 40 (39.6) 39 (40.2) 79 (39.9)
P value 0.9311
Age (years)
Mean ± SD 33.5 ± 11.0 34.2 ± 11.2 33.9 ± 11.1
Range 18 – 61 18 – 58 18 – 61
P value 0.6477
Duration of sore throat, n (%)
1 day 24 (23.8) 19 (19.6) 43 (21.7)
2 days 39 (38.6) 31 (32.0) 70 (35.4)
3 days 37 (36.6) 43 (44.3) 80 (40.4)
4 days 0 (0.0) 3 (3.1) 3 (1.5)
5 days 1 (1.0) 1 (1.0) 2 (1.0)
P value 0.1250
Pain severity, n (%)
Moderate 70 (69.3) 64 (66.0) 134 (67.7)
Severe 31 (30.7) 33 (34.0) 64 (32.3)
P value 0.6168
Mean TPA score ± SD 8.0 ± 2.26 8.1 ± 2.58 8.1 ± 2.42
P value 0.7630
TPA - size of tonsils, n (%)
Normal or absent 27 (26.7) 25 (25.8) 52 (26.3)
Slightly enlarged 42 (41.6) 37 (38.1) 79 (39.9)
Moderately enlarged 27 (26.7) 31 (32.0) 58 (29.3)
Much enlarged 5 (5.0) 4 (4.1) 9 (4.5)
P value 0.6635
PrAoI, n (%)
No inflammation 0 (0.0) 1 (1.1) 1 (0.5)
Mild inflammation 42 (41.6) 37 (38.5) 79 (40.1)
Moderate inflammation 52 (51.5) 53 (55.2) 105 (53.3)
Severe inflammation 7 (6.9) 5 (5.2) 12 (6.1)
P value 0.9550
Mean STPIS score ± SD 79.1 ± 8.1 79.1 ± 8.4 79.1 ± 8.2
P value 0.9972
Mean DSS score ± SD 77.9 ± 10.6 78.2 ± 10.4 78.0 ± 10.5
P value 0.8173
Mean SwoTS score ± SD 76.0 ± 12.9 76.0 ± 12.8 76.0 ± 12.8
P value 0.9739
DSS, Difficulty Swallowing Scale; PrAoI, Practitioner’s Assessment of Inflammation;
SD, standard deviation; STPIS, Sore Throat Pain Intensity Scale; SwoTS, Swollen
Throat Scale; TPA, Tonsillo-Pharyngitis Assessment.
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had comparable baseline clinical features (P >0.1 for dif-
ferences between groups). Only 4.1% of the patients had
group A beta-hemolytic streptococcal pharyngitis, with
no difference between the treatment groups (3.0% in the
flurbiprofen 8.75 mg group, 5.2% in the placebo group;
P >0.1), and most patients had evidence of moderate or
severe pharyngeal inflammation (Table 2). The pretreat-
ment severity of all three pharyngeal symptoms (on the
STPIS, DSS, and SwoTS) was also comparable (all P >0.1).
Most patients had moderate pain at baseline (69.3% of pa-
tients in the flurbiprofen 8.75 mg treatment group and
66% in the placebo group; P >0.1) (Table 2).
Efficacy
On average, patients used 4.7 lozenges (standard deviation
(SD) 0.96, range 2 to 8) over the initial 24-hour treatment
period. For the study’s primary endpoint (SPID24), pa-
tients in the flurbiprofen 8.75 mg group reported a 59%
greater reduction in pain than patients taking placebo
(difference of –196.6 mm× h; 95% confidence interval
(CI) –321.0 to −72.2; P <0.01; Figure 3A). Patients taking
flurbiprofen 8.75 mg lozenges also experienced a 45%
greater relief of difficulty swallowing (difference of −179.7;
95% CI −305.7 to −53.8; P <0.01; Figure 3B) and a 44%
greater reduction of swollen throat than patients taking
placebo lozenges over the 24-hour period (difference of
−168.4; 95% CI −293.7 to −43.1; P <0.01; Figure 3C). A
greater percentage (53.6%) of patients in the flurbiprofen
8.75 mg treatment group reported they were ‘satisfied’,
‘very satisfied’, or ‘extremely satisfied’ with treatment than
patients in the placebo group (38.5%; P <0.05).
When the effects of a single dose were analyzed, a sta-
tistically significant reduction in sore throat pain inten-
sity was observed for patients treated with flurbiprofen
8.75 mg lozenge compared with placebo up to three
hours post-dose (P <0.01). Reductions in absolute DSS
and SwoTS levels were also observed at each hourly as-
sessment up to and including four hours post-dose for
patients in the flurbiprofen 8.75 mg treatment group
compared with placebo (all P <0.05) (Figure 4A-C). Sig-
nificantly greater percentages of flurbiprofen-treated pa-
tients reported at least a 20% reduction in sore throat
pain intensity than patients in the placebo treatment
group (61.4 and 37.1% respectively; P <0.001), in diffi-
culty swallowing (57.4 and 36.1% respectively; P <0.01),
and in swollen throat (63.4 and 40.2%; P <0.01). Using a
cumulative responder analysis of patients achieving at
least 20% reduction in sore throat pain intensity (Figure 5),
the ARD between flurbiprofen and placebo was 0.22
(NNT 4.5) at one hour post-dose and 0.24 (NNT 4.1) at
six hours post-dose.
Sore throat relief was significantly greater for patients
who used the flurbiprofen 8.75 mg lozenge than placeboat one hour (mean (SD) scores 1.8 (1.22) and 1.2 (1.15),
respectively; P <0.01) and two hours (mean (SD) scores
2.0 (1.23) and 1.3 (1.24); P <0.0001), the two time points
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Figure 3 Efficacy of multiple doses of flurbiprofen 8.75 mg or
placebo lozenges over 24 hours. ANOVA was used to compare
flurbiprofen 8.75 mg and placebo groups for the time-weighted
summed differences in LS mean scores over 24 hours for A) sore throat
pain (on the STPIS), B) difficulty swallowing (on the DSS), and C) swollen
throat (on the SwoTS). ANOVA, analysis of variance; CI, confidence
interval; DSS, Difficulty Swallowing Scale; h, hour; LS, least square; STPIS,
Sore Throat Pain Intensity Scale; SwoTS, Swollen Throat Scale.
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days two to seven experienced a 38.0% greater relief of
sore throat pain (difference of −8.2; 95% CI −17.1 to 0.7;
P = 0.07), a 36.9% greater improvement in difficulty swal-
lowing (difference of −7.5; 95% CI −16.2 to 1.3; P = 0.09),
and a 45.0% greater relief of swollen throat compared
with patients taking placebo lozenges (difference of −8.1;
95% CI −16.8 to 0.6; P = 0.07).
Safety
The percentage of patients who reported any AE in the
first 24 hours of the study (when most lozenges were
consumed) was similar for both treatment groups (25.7%
in the flurbiprofen 8.75 mg group, 19.6% in the placebo
group; P >0.1). Most AEs were related to URTI symp-
toms (headache and throat irritation). Severe AEs were
reported by 1.0% of patients in both treatment groups
(P >0.1); the incidence of gastrointestinal AEs related to
study treatment was also similar between groups (occur-
ring in 3.0 and 1.0% of patients in the flurbiprofen
8.75 mg and placebo treatment groups, respectively;
P >0.1). Over seven days, the proportion of patients
reporting any AE remained similar between the treatment
groups (33.7% in the flurbiprofen 8.75 mg group, 28.9% in
the placebo group; P >0.1), as was the incidence of
treatment-related gastrointestinal AEs (3.0% in the flurbi-
profen 8.75 mg group, 2.1% in the placebo group; P >0.1).
Discussion
To evaluate the multiple-dose effects of an analgesic-
containing lozenge in patients with sore throat, a self-
limited inflammatory pain condition, this randomized,
double-blind, placebo-controlled study required strict
adherence to basic principles of clinical trial design and
methodology. By tightening the admission requirements
(specificity of diagnosis, acute onset, and severity of
throat symptoms), eliminating confounding clinical fea-
tures, using validated rating scales for different throat
symptoms (not only pain intensity), and measuring these
symptoms over the first 24-hour period when throat
symptoms are most prominent and require repeated
treatment, this multiple-dose trial was sufficiently sensi-
tive to differentiate an active analgesic drug from pla-
cebo. The patients were able to detect distinct
differences between the sugar-based, flavored flurbipro-
fen 8.75 mg lozenges and the sugar-based, identically fla-
vored placebo lozenges for the five patient-reported
outcomes (reduction of sore throat pain, difficulty swal-
lowing, swollen throat, sore throat relief, and overall pa-
tient satisfaction).
The study was also sensitive to single-dose effects,
confirming results of previous studies on a single flurbi-
profen lozenge compared with placebo [7-9]. Note-
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Figure 4 Efficacy of a single flurbiprofen 8.75 mg or placebo
lozenge over six hours. ANOVA was used to compare flurbiprofen
8.75 mg (n = 101) and placebo (n = 97 up to two hours, n = 96 from
three to six hours, as one patient withdrew from the study) for the
effects of a single dose on absolute mean change over six hours in
A) sore throat pain (on the STPIS), B) difficulty swallowing (on the
DSS), and C) swollen throat (on the SwoTS). Error bars represent the
95% CIs. *P <0.05, **P <0.01, ***P <0.001 compared with placebo.
ANOVA, analysis of variance; CI, confidence interval; DSS, Difficulty
Swallowing Scale; LS, Least square; STPIS, Sore Throat Pain Intensity
Scale; SwoTS, Swollen Throat Scale.
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the first assessment time point (one hour) on all rating
scales, in peak effects at one to three hours, and dur-
ation lasting for up to four hours on two of the three
scales used to measure hourly effects over six hours.
These effects represented at least a 20% reduction in the
severity of each patient-reported outcome for the major-
ity of flurbiprofen-treated patients: the pharmacologic
effects of this low dose of flurbiprofen were distinctly
differentiated from the demulcent effects of the lozenge
base itself.
While this study did achieve its objective of demon-
strating pharmacologic activity after multiple doses of
study medication, there was one major limitation. Ap-
proximately 40% of the patients reported the onset of
throat symptoms in the previous three days (and five pa-
tients were inadvertently admitted with onset in the pre-
vious four to five days). Therefore, the first 24 hours of
the study was actually the fourth, fifth, or sixth day of
these patients’ symptoms. Acute sore throat is an illness
of short duration, with 85% improving within seven days
[6]. This natural course may explain why the differences
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Figure 5 Cumulative percentage of patients achieving at least a
20% reduction from baseline in Sore Throat Pain Intensity Scale
(STPIS) score.
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prove assay sensitivity after the initial stages of sore
throat (when symptoms are likely to be worst), future
multiple-dose studies on sore throat treatments should
restrict recruitment to patients with an onset of only
one or two days.
Conclusions
In this study, using specific design and methods, the sore
throat (pharyngitis) pain model demonstrated that mul-
tiple doses of flurbiprofen 8.75 mg lozenges are an ef-
fective, well-tolerated treatment for patients with sore
throat. Efficacy was evident for the patient-reported out-
comes of pain intensity, pain relief, and swollen throat
as well as throat function (swallowing) and overall pa-
tient satisfaction. We therefore conclude that this pain
model is a practical and efficient multiple-dose assay for
the safety and efficacy of analgesic agents.
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